USPTO serial 86834490
AMGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 16, 2020
- Examiner
- TOY, JOSHUA SPENCER JOLL
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with AMGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $2,493*
Plus Government fees of $2,975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Thousand Oaks, CA, US
Thousand Oaks, CA, US
Thousand Oaks, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Elsa D. Lemoine
Elsa D. Lemoine Amgen Inc.One Amgen Center DriveTrademark Operations - MS-28-5AThousand Oaks, CA 91320-1799Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals for the treatment of cardiovascular, cancer, bone, neurological nephrological and inflammation disease and disorders; pharmaceutical preparations for the treatment of anemia, ankylosing spondylitis, arthritis, cancer, cardiovascular conditions, collection by leukopheresis, effects of myelosuppressive chemotherapy, effects of myelosuppressive doses of radiation, glandular disorders, hormone disorders, hypercalcemia, hyperparathyroidism, hyperphosphatemia, kidney disorders and disease, migraine, neutropenia, osteoporosis, parathyroid disorders, psoriasis, reduction of red blood cell transfusions, renal disorders, thrombocytopenia; prescription pharmaceuticals for the treatment of anemia, ankylosing spondylitis, arthritis, cancer, cardiovascular conditions, collection by leukopheresis, effects of myelosuppressive chemotherapy, effects of myelosuppressive doses of radiation, glandular disorders, hormone disorders, hypercalcemia, hyperparathyroidism, hyperphosphatemia, kidney disorders and disease, migraine, neutropenia, osteoporosis, parathyroid disorders, psoriasis, reduction of red blood cell transfusions, renal disorders, thrombocytopenia; and pre-filled syringes and vials containing pharmaceutical preparations for the treatment of the aforementioned diseases and disorders and complications associated therewith | ACTIVE | Jan 1, 1990 |
| 010 | Drug delivery devices in the nature of drug delivery systems; drug delivery systems; injection device for pharmaceutical preparations; injectors for medical purposes in the nature of medical fluid injectors | ACTIVE | Jan 1, 2007 |
| 035 | Online wholesale services by direct solicitation by salespersons directed to end-users featuring pharmaceuticals; referral services in the field of treatment for cancer, chemotherapy and pharmaceutical products in the nature of medical referrals; business administration of prescription drug co-payment programs; business administration of patient reimbursement programs; referral services in the field of co-pay assistance programs in the nature of providing insurance agent referrals; providing an online commercial information directory in the field of patient support featuring information regarding healthcare providers, sites at which subcutaneous injections could be administered and retail pharmacies or specialty pharmacies where patients could obtain pharmaceutical preparations | ACTIVE | Jan 1, 2010 |
| 036 | Providing healthcare administration, namely, providing insurance verification and prior authorization services for others | ACTIVE | Jan 1, 2015 |
| 041 | Educational services, namely, development and dissemination of printed educational materials of others in the fields of pharmaceutical products and treatment of medical disorders; conducting seminars in the field of the use of prescription pharmaceutical products for medical disorders; educational and entertainment services, namely, providing a motivational and educational speaker featuring information regarding medical disorders; training services in the field of patient support services relating to treatment of medical disorders; providing on-line electronic newsletters delivered by email in the field of the treatment of medical disorders | ACTIVE | Jan 1, 2010 |
| 042 | Pharmaceutical research and development services; biological research; chemical research; medical research, namely, conducting clinical trials for others | ACTIVE | Jan 1, 1990 |
| 044 | Patient support services relating to the treatment of medical disorders, namely, providing online information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services via a global computer network; providing health and medical information about medical disorders; information services, namely, providing medical information to cancer patients; providing patient support services relating to cancer and cancer treatment in the nature of an Internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; providing information about bone health in patients with cancer by offering customized medical information and practical advice for communicating about bone health with healthcare providers; information services, namely, providing medical consultancy and advisory services via a global computer network in the field of cancer-related bone health; providing medical information and patient support services, namely, providing pharmaceutical advice and consultation in the nature of providing online information regarding bone health, the prevention of osteoporosis and the treatment and management of osteoporosis and bone disease, and pharmaceutical preparations for the treatment of osteoporosis; medical report services in the nature of providing medical reports regarding patients being treated for osteoporosis and bone disease; providing medical consultancy and advisory services via a global computer network in the field of cancer treatment and chemotherapy; providing medical information and patient support services, namely, pharmaceutical advice and consultation in the nature of providing online information regarding immune thrombocytopenic purpura; providing health and medical information about immune thrombocytopenic purpura; information services, namely, providing medical information to immune thrombocytopenic purpura patients; patient support services relating to treatment of medical disorders, namely, providing information to patients and families of patients in the field of administering medication, and patient medical information where patients can inquire about medical issues and procedures from medical personnel | ACTIVE | Jan 1, 2010 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Amgen Inc.
- Other trademarks owned by Amgen Inc.
- Other trademarks owned by Amgen Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AMGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 3, 2026 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Sep 3, 2026 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Sep 3, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 9, 2026 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jun 16, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 25, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 25, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 25, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 25, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 25, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 29, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 29, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 29, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 29, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 29, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 29, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 16, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 15, 2020 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| May 14, 2020 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Apr 29, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 28, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 28, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 28, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2019 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2019 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 10, 2019 | IUAF | USE AMENDMENT FILED | — |
| Oct 10, 2019 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Apr 4, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 3, 2019 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Mar 28, 2019 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 28, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 7, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 7, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 11, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 7, 2018 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 7, 2018 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 7, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 2, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 15, 2018 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 13, 2018 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 13, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 13, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 12, 2017 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 12, 2017 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 31, 2017 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 31, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 29, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 27, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 27, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 27, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 11, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 16, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 16, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 27, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 14, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 13, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 13, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 13, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 13, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 11, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 11, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 11, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 21, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 20, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 20, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 8, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 8, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 8, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 4, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 3, 2015 | NWAP | NEW APPLICATION ENTERED | — |